ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

Ferric sodium pyrophosphate

HCID 24862
ノート反応
基本情報名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
10045-87-1
標準SMILES
O=P([O-])([O-])OP(=O)([O-])[O-].[Fe+3].[Na+]
InChIKey
XWQGIDJIEPIQBD-UHFFFAOYSA-J
分子式
FeNaO7P2
平均分子量
252.78 g/mol
単同位体質量
252.836631

名称と識別子

優先名称
Ferric sodium pyrophosphate
IUPAC
sodium;iron(3+);phosphonato phosphate
英語名
FERRICSODIUMPYROPHOSPHATE
分子式
Fe·xH4O7P2·xNa
分子量
0

名称と別名

Ferric sodium pyrophosphate10045-87-1Sodium ferric pyrophosphateIron sodium diphosphateIRON SODIUM PYROPHOSPHATENGH4LHX6XQIron(III) sodium pyrophosphateDiphosphoric acid, iron(3+) sodium salt (1:1:1)Iron(3+) sodium pyrophosphateHSDB 455EINECS 233-150-2Pyrophosphoric acid, iron(3+) sodium salt (1:1:1)
名称をさらに表示
Iron sodium pyrophosphate (NaFeP2O7)SODIUM IRON (III) PYROPHOSPHATEFERRIC SODIUM PYROPHOSPHATE [MI]IRON SODIUM PYROPHOSPHATE [HSDB]FERRIC SODIUM PYROPHOSPHATE [WHO-DD]IRON SODIUM PYROPHOSPHATE (FENAP2O7)RefChem:599090233-150-2

データベース識別子

CAS
10045-87-1、10213-96-4
PubChem CID
24862
DTXSID
DTXSID10905512
UNII
NGH4LHX6XQ
EC Number
233-150-2
Nikkaji
J241.247K

物性

構造計算による物性

極性表面積
136 Ų
水素結合供与体数
0
水素結合受容体数
7
回転可能結合数
0
重原子数
11
形式電荷
0
複雑度
124

実験および物理化学的性質

Food AdditivesUse unspecified -> FDA Substance added to food
DensityBulk density: 1.4-1.6
Color/FormWhite powder
SolubilitySoluble in hydrochloric acid; insoluble in water

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

危険有害性情報

FDA RequirementsFerric sodium pyrophosphate used as a nutrient and/or dietary supplement in animal drugs, feeds, and related products is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Federal Drinking Water GuidelinesEPA 300 ug/L /Iron/
Skin, Eye, and Respiratory IrritationsIf inhaled, iron is a local irritant to the lung and gastrointestinal tract. /Iron compounds/

安全と保護具

Disposal Methods · 2 件

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

The following wastewater treatment technologies have been investigated for iron (Fe+2): Concentration process: Biological treatment. /Iron (Fe+2)/

Preventive Measures · 2 件

SRP: The scientific literature for the use of contact lenses in industry is conflicting. The benefit or detrimental effects of wearing contact lenses depend not only upon the substance, but also on factors including the form of the substance, characteristics and duration of the exposure, the uses of other eye protection equipment, and the hygiene of the lenses. However, there may be individual substances whose irritating or corrosive properties are such that the wearing of contact lenses would be harmful to the eye. In those specific cases, contact lenses should not be worn. In any event, the usual eye protection equipment should be worn even when contact lenses are in place.

All ... /iron/ preparations should be kept in child-proof bottles. /Iron preparations/

化学と産業

用途と製造

UsesNutrient and/or dietary supplement food additive.
U.S. Exports · 2 件

(1977) No Data

(1979) No Data

U.S. Imports · 2 件

(1977) No Data

(1979) No Data

U.S. Production · 2 件

(1977) NOT PRODUCED COMMERCIALLY IN US

(1979) NOT PRODUCED COMMERCIALLY IN US

Formulations/PreparationsA complex sodium iron (or ferric) pyrophosphate(sip), Na8Fe4(P2O7)5.xH2O (formula derived from the molecular ratios obtained by chemical analysis), also is used to some extent as an iron-enrichment compound in food formulations.
General Manufacturing Information · 4 件

Commercial product contains 15.5-16.5% Fe and 50.5-52.5% phosphorus pentoxide.

Food enrichment. Less prone to induce rancidity than orthophosphates.

As feed source of iron...it may...need official reevaluation. In chick trials it has very poor biologic availability (<20%, compared to 100% for the ferrous sulfate standard).

VET: Nutrient, iron source.

サプライヤー40 社

江西益众化工有限公司15307925109 15350027073 · [email protected]
合肥翰刚医药科技有限公司+8618062405514 · [email protected]
河北创之源生物科技有限公司13012111162
陕西晨明生物科技有限公司15529026321
武汉吉业升化工有限公司027-83360216 18040558719 · [email protected]

関連反応

0 件
反応記録を作成

現在のフィルター条件では反応記録がありません。

化合物ノート

読み込み中…

このページの内容基本情報名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Other Standards Regulations and Guidelines · 2 件

Australia, Belgium, Finland, Italy, Netherlands, & Switzerland: 1 mg/cu m. /Iron salts/

Australia (1978); Belgium (1978); Finland (1975); Italy (1978); Netherlands (1978); and Switzerland (1978): 1 mg/cu m. /From table/ /Ferric salts, as Fe/

毒性情報

Non-Human Toxicity Excerpts · 2 件

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Teratologic evaluations of ferrous sulfate and ferric sodium pyrophosphate have been carried out in rats and mice. For studies in mice, groups each of approximately 24 pregnant albino CD-1 mice were dosed by oral intubation with the test substance from day 6 through day 16 of gestation. Body weights were recorded on days 0, 6, 11, 15 and 17 of gestation. On day 17, all dams were subjected to cesarean section and the number of implantation sites, resorption sites and live and dead fetuses recorded. The body weight of the live pups was also taken. The urinogenital tract of each dam was examined in detail for abnormality. All fetuses were examined for the presence of external congenital abnormalities. One-third of the fetuses were examined for visceral abnormalities and the remaining two-thirds for skeletal abnormalities. For studies in rats, groups each of approximately 24 pregnant female albino rats (Wistar derived stock) were dosed daily by oral intubation from day 6 of gestation through day 15. Body weights were recorded on days 0, 6, 11, 15 and 20. On day 20, all dams were subjected to cesarean section, and observations for dams and fetuses similar to those described in the mouse study were carried out. ...Ferric sodium pyrophosphate showed no maternal toxicity or teratogenic effects at dose levels up to 160 mg/kg bw in mice or rats.

/GENOTOXICITY/ A number of ferrous and ferric salts have been tested for mutagenicity using the following organisms. Saccharomyces cerevisiae strain D-4, Salmonella typhimurium strains. TA-1535, TA-1537, and TA-1538 with and without activation. Plate tests as well as suspension tests were run with the Salmonella strains. ...Sodium ferric pyrophosphate /was/ inactive in all the systems used.

Antidote and Emergency Treatment · 5 件

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for shock and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool. /Iron and related compounds/

Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious. Monitor cardiac rhythm and treat arrhythmias if necessary ... . Start an IV with lactated Ringer's /SRP: "To keep open", minimal flow rate/. Watch for signs of fluid overload. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Iron and related compounds/

Maintain an open airway and assist ventilation if necessary. Treat shock caused by hemorrhagic gastrointestinitis aggressively with intravenous crystalloid fluids, and replace blood if needed. Patients are often markedly hypovolemic owing to gastrointestinal losses and third spacing of fluids into the intestinal wall and interstitial space. Treat coma, seizures, and metabolic acidosis if they occur. For seriously intoxicated victims (eg, shock, severe acidosis, and/or serum iron > 500-600 mcg/dL) administer deferoxamine. Monitor the urine for the urine for the characteristic orange or pink deferoxamine-iron complex. Therapy may be stopped when the urine returns to normal or when the serum iron level decreases to the normal range. Prolonged deferoxamine has been associated with adult respiratory distress syndrome and Yersinia sepsis.

Activated charcoal is not effective. Ipecac is not recommended, because it can aggravate iron-induced gastrointestinal irritation and interfere with whole bowel irrigation. Consider gastric lavage if product was a liquid formulation or tablets were chewed. Do-not use phosphate-containing solutions for lavage; these may result in life-threatening hypernatremia, hyperphosphatemia, and hypocalcemia. Bicarbonate and deferoxamine lavage are of doubtful efficacy. Deferoxamine lavage is not effective and may enhance iron absorption. Whole-bowel irrigation is very effective for ingested tablets and may be considered first-line treatment, especially if large numbers of tablets are visible on plain abdominal x-ray. Massive ingestions may lead to concretions or bezoars. Repeated or prolonged whole-bowel irrigation may remove tablets. Endoscopy or surgical gastrotomy is rarely required.

Hemodialysis and hemoperfusion are not effective for removing iron but may be necessary to remove iron-deferoxamine complex in patients with renal failure. Exchange transfusion is occasionally used for massive pediatric ingestions but is of questionable efficacy.

法規制情報

FDA RequirementsFerric sodium pyrophosphate used as a nutrient and/or dietary supplement in animal drugs, feeds, and related products is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Federal Drinking Water GuidelinesEPA 300 ug/L /Iron/
武汉吉业升化工有限公司15387013945 · [email protected]
江西瑞威尔生物科技有限公司18502762009 · [email protected]
河北鸿韬生物工程有限公司15512737321
武汉吉业升化工有限公司13545274181 · [email protected]
西安拉维亚生物科技有限公司13022827400 18629620162 · [email protected]
武汉吉业升化工有限公司027-13545242311 13545242311 · [email protected]
山东思扬生物科技有限公司15666921172
武汉吉业升化工有限公司15927657268 · [email protected]
重庆星灿医药科技有限公司13594048950 19923294409 · [email protected]
康迪斯化工(湖北)有限公司13125172151 · [email protected]
湖北巨胜科技有限公司027-59599241 18871490274 · [email protected]
HANGZHOU LEAP CHEM CO., LTD.+86-571-87711850 +86-15355479329 · [email protected]
武汉吉业升化工有限公司13343438917 · [email protected]
武汉吉业升化工有限公司15927120776 · [email protected]
武汉吉业升化工有限公司15307169873 · [email protected]
山东萍聚生物科技有限公司18613662662; 18613662662
山东爱采生物科技有限公司13573016375 13573016375
湖北海嘉生物科技有限公司15071111164
武汉卡诺斯科技有限公司18064039730 · [email protected]
Shaanxi Dideu New Materials Co. Ltd18192503167 · [email protected]
湖北东曹化学科技有限公司027-83238443 13343438265 · [email protected]
爆牛贸易重庆有限公司+86-023-6139-8061 +86-86-13650506873 · [email protected]
武汉吉业升化工有限公司15927657172 · [email protected]
SHANGHAI KEAN TECHNOLOGY CO., LTD.+8613817748580 · [email protected]
江苏采薇生物科技有限公司13338976321
山东新雄生物科技有限公司15666663101
江苏华策生物科技有限公司13023333306
江西浩硕化工有限公司15307027737 15347922863 · [email protected]
四川焕煦生物科技有限公司15682000004
南京松冠生物科技有限公司13584088977
Hefei TNJ Chemical Industry Co.,Ltd.+86-0551-65418671 +86-189 4982 3763 · [email protected]
武汉吉业升化工有限公司027-1537705-6467 15377056467 · [email protected]
广东明通生物科技有限公司13112222280
Henan Fengda Chemical Co., Ltd+86-371-86557731 +86-13613820652 · [email protected]
武汉市聚舜化工有限公司13349917800 13349917800 · [email protected]